NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it has begun human testing of its light-based detection technology for Barrett’s Esophagus, a precursor for esophageal cancer. The technology is being jointly developed with Konica Minolta Opto of Japan.
